Opendata, web and dolomites

HD4HF

Heart Damper: a revolutionary device for Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HD4HF project word cloud

Explore the words cloud of the HD4HF project. It provides you a very rough idea of what is the project "HD4HF" about.

transplantation    quick    instrument    12    contractile    worldwide    stage    actual    rejection    individual    patent    life    patient    moves    expectancy    implanted    apart    total    granted    public    respect    38    hf    2030    reducing    pharmacological    artificial    procedure    economic    ventricle    fitted    viability    external    household    billion    risk    quality    cardiac    eucardia    social    ease    symptoms    cure    penetration    sufficient    hd    impossible    65    assist    inevitably    million    damper    therapies    longer    healthcare    implantable    left    treat    surgical    epidemic    sources    minimally    community    rare    treatments    owned    health    patients    age    protected    upwards    issue    staggering    15    family    people    stably    transapical    countries    tah    productivity    sme    market    give    energy    residual    solution    supports    once    heart    cacapacity    alone    time    introduction    segment    designed    invasive    device    independently    innovation    vad    ventricular    feasibility    80    innovative    systolic    intended   

Project "HD4HF" data sheet

The following table provides information about the project.

Coordinator
EUCARDIA SRL 

Organization address
address: VIA GIACOMO LEOPARDI 7
city: MILANO
postcode: 20123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUCARDIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

This project supports the market introduction of the Heart Damper (HD), a very innovative implantable cardiac device, intended to provide a simple, quick and cost-effective solution to treat patients affected by systolic heart failure.

Heart Failure (HF) is a growing epidemic and a major public health issue: only in EU and US it affects today about 15 million people, with an expected growth of about 38% by 2030. 2 million of these patients are affected by advanced heart failure: a phase in which the pharmacological therapies alone are no longer sufficient to manage the symptoms. Late stage treatments, such as Ventricular Assist Device (VAD) or Total Artificial Heart (TAH) are indeed inevitably associated with high risk of rejection and low quality of life. HF has no actual cure apart from heart transplantation, which is very rare and impossible for people over 65 (80% of HF patients). In addition, HF has a significant social cost, as it doesn’t affect only the individual patient, but also his family and his community. In the US, for example, the costs related to the loss of work and household productivity are estimated at $ 8.2 billion/year (by 2030, $12.3 billion/year).

The Heart Damper, a minimally invasive cardiac device, will make it possible to give patients a longer and better life expectancy, independently from their age, at the same time reducing the staggering associated healthcare costs. Designed to be stably fitted into the left ventricle by a simple transapical surgical procedure, once implanted it moves upwards exploiting the residual contractile cacapacity of the heart, without any need of external energy sources. The device is protected by a patent fully owned by Eucardia, which has been granted in Europe, US and other major countries worldwide.

The SME 1 Instrument will enable Eucardia to assess in detail the technical feasibility and economic viability of its innovation, in order to ease HD market penetration, in respect of HF market segment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HD4HF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HD4HF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More